• − Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −
  • − Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) −
  • − Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) −
  • − Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients –